Compare NIM & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NIM | INO |
|---|---|---|
| Founded | 1992 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.7M | 100.4M |
| IPO Year | N/A | 1999 |
| Metric | NIM | INO |
|---|---|---|
| Price | $9.22 | $0.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 14.5K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,220,086.00 |
| Revenue This Year | N/A | $20,156.19 |
| Revenue Next Year | N/A | $421.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $9.02 | $0.95 |
| 52 Week High | $9.94 | $2.86 |
| Indicator | NIM | INO |
|---|---|---|
| Relative Strength Index (RSI) | 39.56 | 40.42 |
| Support Level | $9.23 | $1.03 |
| Resistance Level | $9.45 | $1.24 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 3.70 | 34.57 |
Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its primary investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital. Its secondary investment objective is to enhance portfolio value relative to the municipal bond market through investments in tax-exempt municipal obligations that are underrated or undervalued, or that represent municipal market sectors that are undervalued. The fund has single operating segment.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.